TrialArthritis care & research2012

Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year.

Jeffrey R Curtis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.